Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Providence, Rhode Island 02903


Purpose:

Phase 2 single-institution trial of early systemic central nervous system prophylaxis in high-risk diffuse large B-cell lymphoma


Study summary:

This is a prospective phase 2 clinical trial of systemic central nervous system prophylaxis among patients with diffuse large B-cell lymphoma at high risk of central nervous system recurrence. The main objective is to evaluate safety and efficacy of early institution of intensive central nervous system prophylaxis in a high-risk group to minimize the risk of a devastating central nervous system recurrence. Patients receive standard primary immunochemotherapy with an addition of planned central nervous system prophylaxis courses on or around day 15 of cycles 2, 4, and 6. Growth factor support and Pneumocystis jirovecii prophylaxis is required. The primary endpoint of this pilot study is protocol-defined toxicity, whereas efficacy (cumulative incidence of central nervous system recurrence) will be a secondary endpoint.


Criteria:

Inclusion Criteria: - New diagnosis of diffuse large B-cell lymphoma, planned first-line therapy using the standard rituximab- and anthracycline-containing regimens - No central nervous system involvement on initial staging - Performance status of 0 or 1 (Eastern Cooperative Oncology Group scale) - Renal function: creatinine clearance >45 ml/min - Not pregnant; agreeable to contraception - Written informed consent - High risk for central nervous system recurrence as determined by one of the following high-risk features: 1. high central nervous system International Prognostic Index, 2. testicular, breast, or uterine involvement, 3. dual expresser or double/triple-hit status, 4. HIV positive status, or 5. Molecularly defined high-risk subtype. Exclusion Criteria: - pregancy - unable to provide informed consent - significant comorbidity in the investigator's judgement


NCT ID:

NCT03719560


Primary Contact:

Principal Investigator
Adam J Olszewski, MD
Rhode Island Hospital

Kayla Rosati
Phone: 401-863-3000
Email: kayla_rosati@brown.edu


Backup Contact:

N/A


Location Contact:

Providence, Rhode Island 02903
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.